KCM
ONCT

Kennedy Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Kennedy Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-29,368
Closed -$203K – 722
2023
Q2 		$203K Hold
29,368
– – ﹤0.01% 653
2023
Q1 		$461K Buy
29,368
+15,956
+119% +$314K 0.01% 565
2022
Q4 		$268K Buy
+13,412
New +$267K 0.01% 587

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Kennedy Capital Management's ONCT Position: Q3 2023 in Review

Kennedy Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2023, closing a stake of 29,368 shares — an estimated $203K sold.

Kennedy Capital Management first reported a position in ONCT in Q4 2022 and held it in 3 quarters. The position peaked at $461K in Q1 2023. 50 funds tracked by Wall St. Rank hold ONCT as of Q3 2023.

  • Kennedy Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 29,368 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $203K.
  • Kennedy Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2022 and held it in 3 quarters.
  • Kennedy Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $461K in Q1 2023.
  • 50 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Kennedy Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.